Literature DB >> 23486770

A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system.

Curt D Sigmund.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23486770      PMCID： PMC3905617          DOI： 10.1161/ATVBAHA.112.301125

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  24 in total

1.  Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells.

Authors:  K Takeda; T Ichiki; T Tokunou; Y Funakoshi; N Iino; K Hirano; H Kanaide; A Takeshita
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

2.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes.

Authors:  R A Hegele; C M Anderson; J Wang; D C Jones; H Cao
Journal:  Genome Res       Date:  2000-05       Impact factor: 9.043

4.  Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.

Authors:  Quy N Diep; Mohammed El Mabrouk; Jeffrey S Cohn; Dierk Endemann; Farhad Amiri; Agostino Virdis; Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Circulation       Date:  2002-05-14       Impact factor: 29.690

5.  Unbuckling lipodystrophy from insulin resistance and hypertension.

Authors:  Robert A Hegele; Todd Leff
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

6.  Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

Authors:  Stephen C Benson; Harrihar A Pershadsingh; Christopher I Ho; Amar Chittiboyina; Prashant Desai; Michal Pravenec; Nianning Qi; Jiaming Wang; Mitchell A Avery; Theodore W Kurtz
Journal:  Hypertension       Date:  2004-03-08       Impact factor: 10.190

Review 7.  Phenomics, lipodystrophy, and the metabolic syndrome.

Authors:  Robert A Hegele
Journal:  Trends Cardiovasc Med       Date:  2004-05       Impact factor: 6.677

8.  Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.

Authors:  Martine Auclair; Corinne Vigouroux; Franck Boccara; Emilie Capel; Catherine Vigeral; Bruno Guerci; Olivier Lascols; Jacqueline Capeau; Martine Caron-Debarle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-07       Impact factor: 8.311

9.  PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

Authors:  Michael J Ryan; Sean P Didion; Satya Mathur; Frank M Faraci; Curt D Sigmund
Journal:  Hypertension       Date:  2004-01-26       Impact factor: 10.190

10.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

Authors:  David B Savage; Garry D Tan; Carlo L Acerini; Susan A Jebb; Maura Agostini; Mark Gurnell; Rachel L Williams; A Margot Umpleby; E Louise Thomas; Jimmy D Bell; Adrian K Dixon; Fidelma Dunne; Romina Boiani; Saverio Cinti; Antonio Vidal-Puig; Fredrik Karpe; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  Diabetes       Date:  2003-04       Impact factor: 9.461
View more
  5 in total

1.  Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.

Authors:  Jun Zhang; Qing-Qing Hao; Xin Liu; Zhi Jing; Wen-Qing Jia; Shu-Qing Wang; Wei-Ren Xu; Xian-Chao Cheng; Run-Ling Wang
Journal:  Oncotarget       Date:  2017-04-11

2.  RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity.

Authors:  Masashi Mukohda; Shi Fang; Jing Wu; Larry N Agbor; Anand R Nair; Stella-Rita C Ibeawuchi; Chunyan Hu; Xuebo Liu; Ko-Ting Lu; Deng-Fu Guo; Deborah R Davis; Henry L Keen; Frederick W Quelle; Curt D Sigmund
Journal:  J Clin Invest       Date:  2019-03-21       Impact factor: 14.808

Review 3.  Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma.

Authors:  Pimonrat Ketsawatsomkron; Curt D Sigmund
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-03       Impact factor: 2.894

4.  Interference With Endothelial PPAR (Peroxisome Proliferator-Activated Receptor)-γ Causes Accelerated Cerebral Vascular Dysfunction in Response to Endogenous Renin-Angiotensin System Activation.

Authors:  Anand R Nair; Larry N Agbor; Masashi Mukohda; Xuebo Liu; Chunyan Hu; Jing Wu; Curt D Sigmund
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

5.  Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension.

Authors:  Maria Alicia Carrillo-Sepulveda; Henry L Keen; Deborah R Davis; Justin L Grobe; Curt D Sigmund
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.